HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rosa Gil Selected Research

PI103

4/2010The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rosa Gil Research Topics

Disease

4Neoplasms (Cancer)
01/2020 - 04/2010
2Melanoma (Melanoma, Malignant)
06/2010 - 04/2010
1Inflammation (Inflammations)
01/2020
1Skin Neoplasms (Skin Cancer)
10/2014
1Peutz-Jeghers Syndrome (Polyposis, Hamartomatous Intestinal)
10/2014

Drug/Important Bio-Agent (IBA)

1CytokinesIBA
01/2020
1Phosphotransferases (Kinase)IBA
01/2020
1Protein Isoforms (Isoforms)IBA
01/2020
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
10/2014
1Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA
10/2014
1Ribosomal Proteins (Ribosomal Protein)IBA
06/2010
1Pemetrexed (MTA)FDA Link
06/2010
1Cyclin D1IBA
06/2010
1Cytostatic AgentsIBA
06/2010
1Proteins (Proteins, Gene)FDA Link
04/2010
1Sorafenib (BAY 43-9006)FDA Link
04/2010
1PI103IBA
04/2010

Therapy/Procedure

1Precision Medicine
01/2020